Rakovina Therapeutics Stock Current Valuation
| RKV Stock | CAD 0.13 0.01 8.33% |
Valuation analysis of Rakovina Therapeutics helps investors to measure Rakovina Therapeutics' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. End Period Cash Flow is likely to climb to about 911.8 K in 2025, whereas Cash is likely to drop slightly above 373 K in 2025. Fundamental drivers impacting Rakovina Therapeutics' valuation include:
Price Book 3.5241 | Enterprise Value 12 M | Enterprise Value Ebitda (3.39) |
Fairly Valued
Today
Please note that Rakovina Therapeutics' price fluctuation is out of control at this time. Calculation of the real value of Rakovina Therapeutics is based on 3 months time horizon. Increasing Rakovina Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Rakovina stock is determined by what a typical buyer is willing to pay for full or partial control of Rakovina Therapeutics. Since Rakovina Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Rakovina Stock. However, Rakovina Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.13 | Real 0.12 | Hype 0.12 |
The intrinsic value of Rakovina Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Rakovina Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Rakovina Therapeutics helps investors to forecast how Rakovina stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Rakovina Therapeutics more accurately as focusing exclusively on Rakovina Therapeutics' fundamentals will not take into account other important factors: Rakovina Therapeutics Company Current Valuation Analysis
Rakovina Therapeutics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Rakovina Therapeutics Current Valuation | 11.98 M |
Most of Rakovina Therapeutics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Rakovina Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Rakovina Therapeutics has a Current Valuation of 11.98 M. This is 99.92% lower than that of the Biotechnology sector and 99.74% lower than that of the Health Care industry. The current valuation for all Canada stocks is 99.93% higher than that of the company.
Rakovina Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Rakovina Therapeutics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Rakovina Therapeutics could also be used in its relative valuation, which is a method of valuing Rakovina Therapeutics by comparing valuation metrics of similar companies.Rakovina Therapeutics is currently under evaluation in current valuation category among its peers.
Rakovina Fundamentals
| Return On Equity | -0.89 | ||||
| Return On Asset | -0.34 | ||||
| Current Valuation | 11.98 M | ||||
| Shares Outstanding | 90.29 M | ||||
| Shares Owned By Insiders | 20.10 % | ||||
| Number Of Shares Shorted | 37.91 K | ||||
| Price To Book | 3.52 X | ||||
| EBITDA | (2.52 M) | ||||
| Net Income | (2.61 M) | ||||
| Cash And Equivalents | 4.37 M | ||||
| Cash Per Share | 0.06 X | ||||
| Total Debt | 1.49 M | ||||
| Book Value Per Share | 0.03 X | ||||
| Cash Flow From Operations | (1.86 M) | ||||
| Short Ratio | 0.14 X | ||||
| Earnings Per Share | (0.04) X | ||||
| Beta | -0.53 | ||||
| Market Capitalization | 10.83 M | ||||
| Total Asset | 5.15 M | ||||
| Retained Earnings | (10.93 M) | ||||
| Working Capital | 477.88 K | ||||
| Net Asset | 5.15 M |
About Rakovina Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Rakovina Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Rakovina Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Rakovina Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Rakovina Stock Analysis
When running Rakovina Therapeutics' price analysis, check to measure Rakovina Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rakovina Therapeutics is operating at the current time. Most of Rakovina Therapeutics' value examination focuses on studying past and present price action to predict the probability of Rakovina Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rakovina Therapeutics' price. Additionally, you may evaluate how the addition of Rakovina Therapeutics to your portfolios can decrease your overall portfolio volatility.